[177Lu]Ludotadipep Treatment in Patients With Metastatic Castration-resistant Prostate Cancer.

  • End date
    Dec 30, 2022
  • participants needed
  • sponsor
Updated on 15 August 2021


The study aims to evaluate the stability and efficacy after administration of [177Lu]Ludotadipep in patients with metastatic castration resistant prostate cancer (mCRPC), with dose-escalation applied to determine the appropriate dose.


[18F]PSMA PET/CT is conducted at the 2nd screening and only PSMA PET/CT positive patients can be enrolled (PSMA RADS 4 or more).

Dose is administered by differentiated into 5 groups (6 subjects each) and sequentially elevated starting from a low dose to a high dose (505 mCi, 758 mCi, 10010 mCi, 12513 mCi, 15015 mCi).

Condition Metastatic Castration Resistant Prostate Cancer
Treatment [177Lu]Ludotadipep
Clinical Study IdentifierNCT04509557
Last Modified on15 August 2021


Yes No Not Sure

Inclusion Criteria

Among prostate cancer patients with blood testosterone 50ng/dL, mCRPC patients showing radiological progression after standard taxene-based anticancer treatment and 2nd generation hormone agent (abiraterone, enzalutamed, or both)) treatment or patients who are not eligible for such standard medical treatment at the discretion of an investigator or patients who refuse such standard treatment
Patients who are positive on the [18F]PSMA PET/CT imaging
Subjects who were fully informed by an investigator of the study objectives, details, and characteristics of the study drug prior to study enrollment, and had an informed consent form signed by the subject or caretaker or legally acceptable representative
Male patients aged 20 years or older
Subjects who are sexually active and have a female partner of childbearing potential should meet the followings
Subjects should consent to practice contraception by continuously using a male condom from screening, throughout the study, and for at least 6 months after the last dose of the study drug
Subjects should never donate sperms from screening, throughout the study, and for at least 6 months after the last dose of the study drug
Subjects with a partner who is a woman of childbearing potential (including a pregnant or breastfeeding mother) should consent to maintain sexual abstinence or practice double contraception throughout the study Double contraception: Corresponding to 2 or more of the followings - use of a condom, use of a non-hormonal intrauterine device, use of a diaphragm, use of a cervical cap, a sexual partner who has been vasectomized at least 3 months (as of the first screening visit) or a sexual partner medically diagnosed to be sterile
ECOG _ Performance score 2
Life expectancy 6 months

Exclusion Criteria

Subjects determined by an investigator to have a serious medical condition making study conduct difficult
Subjects corresponding to the following conditions 1) Glomerular filtration rate 40 ml/min, 2) hemoglobin level 10.0 g/dL, 3) white cell count 4.0 109/L, 4) platelet count 100 109/L, 5) total bilirubin level 1.5 x upper normal limit, 6) serum albumin level 3.0 g/dL, 7) active ischemic heart disease or heart failure (New York Heart Association Classification III-IV), 8) uncontrolled diabetes/hypertension, 9) hyperkalemia >6.0 mmol/L
Vulnerable subjects (the investigator involved in the study or his/her family, research staff or students of the investigator involved in the study)
Patients with a persistent malignancy other than the prostate cancer
Patients who participated in a therapeutic clinical trial within the past 30 days and administered an investigational product other than standard treatment
Patients are excluded if treatment other than the treatment provided in this study is determined more appropriate as determined by the investigator based on the patient and disease characteristics
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note